[1] |
ZHAO Yihan, LI Ruochen, LIN Yansong.
Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer
[J]. China Oncology, 2025, 35(1): 12-20.
|
[2] |
ZHANG Zhiyue, HE Huijing, SHAN Guangliang, LIN Yansong.
Research progress in epidemiology and risk factors of thyroid cancer
[J]. China Oncology, 2025, 35(1): 21-29.
|
[3] |
GENG Qianqian, YANG Aimin.
Progress and prospect on treatment for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 30-39.
|
[4] |
LI Ruping, YANG Hui.
Current status and future prospects of clinical trials for radioiodine-refractory thyroid cancer
[J]. China Oncology, 2025, 35(1): 40-48.
|
[5] |
WANG Renfei, LU Gaixia.
The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 49-57.
|
[6] |
LIN Qiuyu, WANG Yuxin, LIN Chenghe.
Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 58-67.
|
[7] |
SHEN Jie, LIU Wanlin, WANG Zezhou, MU Sibo, MO Miao, ZHOU Changming, YUAN Jing, WANG Yu, ZHENG Ying, JI Qinghai.
Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database
[J]. China Oncology, 2025, 35(1): 68-76.
|
[8] |
JIANG Xiaotong, LIU Jinchuan, ZHANG Yingqiang, WANG Tong, GUO Ning, SUN Yuqing, SHI Cong, YAN Bing, LIN Yansong.
The role of diagnostic whole body scan in decision-making of 131I treatment for differentiated thyroid cancer
[J]. China Oncology, 2025, 35(1): 77-84.
|
[9] |
XU Yuchen, ZHANG Jian, WANG Yan, LIN Jinyi, ZHOU Yuhong, CHENG Leilei, GE Junbo.
Therapeutic effects of tofacitinib on steroid-resistant immune checkpoint inhibitor-associated myocarditis
[J]. China Oncology, 2024, 34(4): 400-408.
|
[10] |
PAN Yijin, SHI Cong, SUN Yuqing, SUN Di, ZHAO Yihan, ZHANG Jin, LIN Yansong.
Global trends of 131I-therapy for differentiated thyroid cancer in children and adolescents: a bibliometric analysis (1993-2003)
[J]. China Oncology, 2024, 34(12): 1123-1133.
|
[11] |
XUE Liqiong, GUO Ye, CHEN Libo.
Expert consensus on the management of adverse events in patients receiving targeted agents for advanced thyroid cancer (2023 edition)
[J]. China Oncology, 2023, 33(9): 879-888.
|
[12] |
YUAN Xinyue, YAO Yao, CHENG Shuai, ZHENG Xin, ZHANG Yuan.
Clinical study on high-risk factors for contralateral lymph node metastasis in unilateral papillary thyroid carcinoma
[J]. China Oncology, 2023, 33(6): 619-628.
|
[13] |
QU Ning, WANG Yuting, MA Ben, WANG Yu.
Advances in basic research, clinical diagnosis and treatment of thyroid cancer in 2022
[J]. China Oncology, 2023, 33(5): 423-430.
|
[14] |
SUN Di, SUN Yuqing, ZHANG Xin, HUANG Lisha, LIN Yansong.
The relationship between genetic characteristics and clinical characteristics and the efficacy of 131I therapy in children and adolescents with locally advanced or metastatic differentiated thyroid cancer
[J]. China Oncology, 2022, 32(5): 380-387.
|
[15] |
DENG Shuting, FENG Yuan, QIAN Kai, GUO Kai, WANG Zhuoying.
Meta-analysis of the association between gene alterations and distant metastasis of differentiated thyroid carcinoma in children and adolescents
[J]. China Oncology, 2022, 32(5): 388-396.
|